ABOUT CENCORA
Cencora combines core pharmaceutical distribution with innovative business solutions to help our partners across the healthcare spectrum get medications to the patients who need them. Biopharmaceutical companies benefit from the global scale and resources of a company ranked #10 on the Fortune 500, combined with local expertise provided by more than 51,000 team members worldwide. Learn more at www.cencora.com.
We help build foundations for successful product submissions, launches, and commercialization across the globe. Our strategic, integrated solutions – encompassing regulatory, safety, market access and more – help accelerate time-to-market while optimizing patient access and revenue from marketed products.
VIDEOS AND WEBINARS
-
![Cencora - oncology webinar]( "Navigating The Regulatory Complexities Of Targeted Medicines In Oncology")
Navigating The Regulatory Complexities Of Targeted Medicines In OncologyExplore the strategic considerations for successfully navigating the regulatory complexities of targeted medicines. Learn about the challenges in translational medicine and key clinical development considerations.
-
![Cencora - Summer Shorts - stats]( "Transforming Drug Development With Statistical Science")
Transforming Drug Development With Statistical ScienceExplore how statistical science and computational biology can accelerate drug development. Learn how innovative trial designs and Bayesian statistics can lead to more efficient and successful clinical trials.
-
![Cencora - Summer Shorts - Thinking Ahead]( "Thinking Ahead: How Integrated Development Plans Improve Product Success")
Thinking Ahead: How Integrated Development Plans Improve Product SuccessHow can integrated development planning reduce development timelines and increase your chances of commercialization success? Industry experts reveal how this approach helps avoid common pitfalls.
-
![Cencora - Shaila Yoshida]( "Understanding The Evolving Landscape Of Anti-Obesity Medication (AOMs)")
Understanding The Evolving Landscape Of Anti-Obesity Medication (AOMs)Discover the evolving landscape of AOMs as a value and access expert shares the latest payer coverage trends, concerns, and strategies. Learn how payers are making critical coverage decisions.
-
![Cencora - Orchestration]( "Connecting Manufacturers And Providers To The Services Needed For Full End-To-End Patient And Order Management")
Connecting Manufacturers And Providers To The Services Needed For Full End-To-End Patient And Order ManagementStreamline complex cell and gene therapy logistics with an integrated platform that connects manufacturers with vital services, providing full visibility and control for a more efficient and successful patient journey.
-
![Strategic Logistics]( "Crafting Scalable Solutions For Maximum Reach And Success")
Crafting Scalable Solutions For Maximum Reach And SuccessIs your supply chain ready for a blockbuster cell and gene therapy launch? Industry leaders discuss selecting partners, managing risk, and scaling operations for maximum reach and success.
CONTACT INFORMATION
Cencora
1 W 1st Ave.
Conshohocken, PA 19428
UNITED STATES
ARTICLES
-
![GettyImages-547131922 research, regulatory, lab]( "Navigating The CGT Landscape: Key Takeaways From The FDA's New FAQ")
The FDA's new FAQ on cell and gene therapy offers a roadmap for developers. Review key insights from the document, including the importance of early engagement with the FDA, CMC considerations, and more.
-
![GettyImages-1081869198 data]( "A Year Of Reflection And Preparation")
The Trial Master File (TMF) landscape in 2025 will require companies to stay attuned to the evolving ICH E6(R3) guidelines and the full implementation of the CTIS.
-
![GettyImages-1310986619 patient]( "A Thoughtful Copay Program Design That Increased Patient Engagement")
Learn how a partnership with a pharmaceutical company to redesign patient support materials resulted in increased patient engagement and copay program utilization.
-
![GettyImages-942955086 lab]( "Sterility Assurance With Louise Ui Fhatharta")
This discussion explores critical aspects of maintaining sterility in pharmaceutical manufacturing, from facility design and environmental monitoring to regulatory compliance and common misconceptions.
-
![GettyImages-1318426446 profile]( "Strategic Management Of The Mature Product Portfolio")
Explore a new outsourcing paradigm that integrates expertise, regulatory knowledge, efficiency, and cost containment, moving beyond traditional low-cost offshore staffing models.
WHITE PAPERS
-
![GettyImages-692413188 lab research]( "Project Orbis Drug Registration 2025")
Project Orbis helps streamline the review and approval of oncology medicinal products through international regulatory collaboration. Learn how this framework can accelerate your regulatory strategy.
-
![GettyImages-158649166 assay]( "Unlock Oncology Success With A Comprehensive Commercialization Guide")
Navigate the complex process of bringing an oncology therapy to market, from regulatory planning to patient access and supply chain logistics, with this comprehensive handbook for developers.
-
![GettyImages-891264822 planning, meeting]( "Why An Integrated Approach Ensures Smooth Entry Into The European Market")
Simplify your EU launch and boost returns. Learn how to manage regulatory hurdles, access a huge patient population, and gain end-to-end commercial support.
PODCASTS
-
![Digital-marketing-GettyImages-1051659276]( "Navigating The Digital Era And Beyond For Engaging Key Decision Makers In Specialty Pharmacy")
Navigating The Digital Era And Beyond For Engaging Key Decision Makers In Specialty PharmacyTune in as experts discuss how biopharma companies can effectively engage healthcare decision-makers in the evolving digital landscape.
-
![Cencora PharmaLex - PlX talks 30]( "An Overview Of Contamination Control Strategy (CCS)")
An Overview Of Contamination Control Strategy (CCS)Join experts Londa Ritchey and Patrick Nieuwenhuizen as they explore the key role of a contamination control strategy in Annex 1 for ensuring patient safety and continuous manufacturing improvement.
-
![Cencora - PharmaLex Talks 28]( "Early Access Programs: What They Are And How To Plan For Them")
Early Access Programs: What They Are And How To Plan For ThemExplore how early access programs are tailored to individual sufferers of rare, ultra-rare, or life-threatening conditions, as well as cohort programs, which target groups of patients afflicted with the same disease.
-
![Cencora - PharmaLex Talks 27]( "Assessing Gaps And Achieving Compliance With Annex 1")
Assessing Gaps And Achieving Compliance With Annex 1In this podcast episode on Annex 1 compliance and gap assessment, Patrick Nieuwenhuizen shares his insights and expertise gleaned from extensive experience in pharmaceutical regulation and compliance.
-
![Cencora - PharmaLex Talks 26]( "Navigating The Process Of Technology Transfer")
Navigating The Process Of Technology TransferOlena Chervonenko, Associate Director Quality Management and Compliance at PharmaLex, provides deeper insights into technology transfer and essential factors for achieving success.
E-BOOKS AND OTHER INSIGHTS
-
![GettyImages-1094847564-scientists-laboratory-flasks-planning-tablet]( "Essential Strategies For Mastering CMC And Avoiding CRLs For CGTs")
Essential Strategies For Mastering CMC And Avoiding CRLs For CGTsCGT developers face rising regulatory challenges around potency, stability, and process control. Find out how proactive planning, expert guidance, and early FDA engagement are key to avoiding delays.
-
![pharmaceutical prescriptions tablets pills 450x300]( "PDABs: An Imperfect Solution To A Complex Issue")
PDABs: An Imperfect Solution To A Complex IssuePrescription Drug Affordability Boards (PDABs) must clearly define goals, improve data analysis, and boost patient engagement to deliver on the promise of lower-cost medicines.
-
![GettyImages-1296133441 canada, canadian flag]( "Unlocking The Voice Of Patients: Are Engagement Initiatives Truly Transforming Canadian HTA Reviews?")
Unlocking The Voice Of Patients: Are Engagement Initiatives Truly Transforming Canadian HTA Reviews?The patient voice is now critical in evaluating new drug treatments. Learn how health technology assessment agencies incorporate patient-reported outcomes to move beyond traditional clinical endpoints.
